It is trading at $13.86 just a bit higher than $13.17, the stock’s 50 day moving average and which is slightly above the 200 day moving average of $12.66. The 50 day moving average went up by +5.25% and the 200 day average went up by +9.48%. Trading volume for Horizon Pharma plc was 3,889K on Tuesday. Volume was down 15.29% under the stocks average daily volume.
Investors are a little more bullish on the company lately if you pay attention to the decrease in short interest. The company realized a fall in short interest of -1.27% as of the latest report on September 29, 2017. Short shares fell from 16,651,885 to 16,439,956 over that timeframe. Days to cover decreased 0.0 to 5.0 and the percentage of shorted shares is 0.10% as of September 29.
Here are a few substantial investment firms who have updated their positions. Creative Planning expanded its ownership by buying 39,501 shares an increase of 65.5% in the quarter. Creative Planning controls 99,849 shares worth $1,266,000. The value of the position overall is up by 76.8%. Rhenman & Partners Asset Management Ab grew its stake by buying 584,772 shares an increase of 24.1% as of 09/30/2017. Rhenman & Partners Asset Management Ab now holds 3,006,862 shares valued at $38,127,000. The total value of its holdings increased 32.6%.
Meeder Asset Management Inc divested its position by selling 1,093 shares a decrease of 85.9% from 06/30/2017 to 09/30/2017. Meeder Asset Management Inc owns 180 shares with a value of $2,000. The value of the position overall is down by 86.7%. Bank Of Montreal /can/ bolstered its investment by buying 1,825 shares an increase of 438.7%. Bank Of Montreal /can/ now controls 2,241 shares valued at $28,000. The value of the position overall is up by 460.0%.
As of the last earnings report the EPS was $-2.70 and is estimated to be $1.07 for the current year with 163,354,000 shares currently outstanding. Next quarter’s EPS is forecasted at $0.23 with next year’s EPS projected to be $1.25.
Horizon Pharma Public Limited Company, launched on December 20, 2011, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Business’s marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium)..